Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488) von Mahé, E., Geldhof, A., Jazra, M., Bergmans, P., Azzabi, A., Seyger, M.M.B.

Volltext

Reversibility of alexithymia with effective treatment of moderate‐to‐severe psoriasis: longitudinal data from EPIDEPSO von Sampogna, F., Puig, L., Spuls, P., Girolomoni, G., Radtke, M.A., Kirby, B., Brunori, M., Bergmans, P., Smirnov, P., Rundle, J., Castiglia, A., Lavie, F., Paul, C.

Volltext

Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study von Sampogna, F., Puig, L., Spuls, P., Girolomoni, G., Radtke, M.A., Kirby, B., Brunori, M., Bergmans, P., Smirnov, P., Rundle, J., Lavie, F., Paul, C., Affleck, A., Antoniou, C., Ayala, F., Bakulev, A., Bam, E., Belinchon, I., Bewley, A., Botella, R., Chasapi, V., Chimenti, S., Cianchini, G., Jong, E., Kort, W., Duval‐Modeste, A.‐B., Fernandez Llaca, J.H., Gaastra, M., Ghislain, P.‐D., Goujon, C., Griffiths, C., Horev‐Yakir, L., Ioannidis, D., Izu, R., Krasagakis, K., Lacour, J.‐P., Lambert, J., Lambert, J., Lopez Estebaranz, J.L., Malara, G., Markham, T., Matz, H., McBride, S., Moseng, D., Nikkels, A., Papakonstantis, M., Pavlotsky, F., Pavlovsky, L., Pellacani, G., Peserico, A., Piccirillo, A., Potenza, C., Prignano, F., Puig Sanz, L., Raboobee, N., Rallis, E., Ramon, M., Reguiai, Z., Riedl, E., Ruer, M., Rustad, L., Salmhofer, W., Sanchez‐Carazo, J.L., Schmutz, J.‐L., Sokolovsky, E., Sotiriadis, D., Tobin, A.‐M., Zhukova, O., Ziv, M.

Volltext

Alexithymia reversion in psoriasis von Sampogna, F., Puig, L., Spuls, P., Girolomoni, G., Radtke, M.A., Kirby, B., Brunori, M., Bergmans, P., Smirnov, P., Rundle, J., Castiglia, A., Lavie, F., Paul, C.

Volltext

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsy... von Schreiner, A, Bergmans, P, Cherubin, P, Keim, S, Llorca, P-M, Cosar, B, Petralia, A, Corrivetti, G, Hargarter, L

Volltext

Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis von Augustin, M., Blome, C., Paul, C., Puig, L., Luger, T., Lambert, J., Chimenti, S., Girolomoni, G., Kragballe, K., Naessens, D., Bergmans, P., Smirnov, P., Barker, J., Reich, K.

Volltext

One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-sever... von Reich, K., Puig, L., Paul, C., Kragballe, K., Luger, T., Lambert, J., Chimenti, S., Girolomoni, G., Nicolas, J.-F., Rizova, E., Brunori, M., Mistry, S., Bergmans, P., Barker, J.

Volltext

Loss of olfaction in de novo and treated Parkinson's disease: Possible implications for early diagnosis von Tissingh, G., Berendse, H.W., Bergmans, P., DeWaard, R, Drukarch, B., Stoof, J.C., Wolters, E.Ch

Volltext

Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT) von Paul, C., Puig, L., Kragballe, K., Luger, T., Lambert, J., Chimenti, S., Girolomoni, G., Nicolas, J.-F., Rizova, E., Lavie, F., Mistry, S., Bergmans, P., Barker, J., Reich, K.

Volltext

银屑病患者的述情障碍逆转 von Sampogna, F., Puig, L., Spuls, P., Girolomoni, G., Radtke, M.A., Kirby, B., Brunori, M., Bergmans, P., Smirnov, P., Rundle, J., Castiglia, A., Lavie, F., Paul, C.

Volltext

Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease von WOLTERS, E. C, JANSEN, E. N. H, TUYNMAN-QUA, H. G, BERGMANS, P. L. M

Volltext

[123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease von Winogrodzka, A, Bergmans, P, Booij, J, van Royen, E A, Stoof, J C, Wolters, E C

Volltext

P.10.17 PROFILE STUDY IN ITALY: A CLASSIFICATION OF ADULT GERD SUBJECTS SUFFERING FROM TYPICAL SYMPTOMS von Cestari, R, Cannaviello, C, De Luca, L, Bergmans, P, Bernareggi, M, Marelli, S

Volltext

L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients von KUIPER, M. A, TEERLINK, T, VISSER, J. J, BERGMANS, P. L. M, SCHELTENS, P, WOLTERS, E. C

Volltext

PSS28 Long-Term Improvement in Patient-Reported Outcomes After Transition From Methotrexate to Ustekinumab in Moderate to Severe Psoriasis: Transit Week 52 Results von Reich, K, Puig, L, Luger, T, Lambert, J, Chimenti, S, Girolomoni, G, Nicolas, J.F, Kragballe, K, Mistry, S, Bergmans, P, Thompson, G, Barker, J, Paul, C

Volltext

Effect of a price display intervention on laboratory test ordering behavior of general practitioners von Muris, Dennis M. J., Molenaers, Max, Nguyen, Trang, Bergmans, Paul W. M. P., van Acker, Bernadette A. C., Krekels, Marielle M. E., Cals, Jochen W. L.

Volltext

[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease von WINOGRODZKA, A, BERGMANS, P, BOOIJ, J, VAN ROYEN, E. A, JANSSEN, A. G. M, WOLTERS, E. Ch

Volltext

Paliperidone palmitate 3-monthly formulation in schizophrenia – baseline interim analysis of a naturalistic, 52-week, prospective study von Hargarter, L., Bergmans, P., Usankova, I., Cherubin, P.

Volltext

P.3.d.034 - Paliperidone palmitate 3-monthly formulation in schizophrenia – baseline interim analysis of a naturalistic, 52-week, prospective study von Hargarter, L., Bergmans, P., Usankova, I., Cherubin, P.

Volltext

Palmitate de palipéridone chez des patients atteints de schizophrénie, non-aigus mais symptomatiques, après échec d’un traitement par aripiprazole von Bergmans, P, Hargarter, L, Cherubin, P, Rancans, E, Bez, Y, Parellada, E, Carpiniello, B, Vidailhet, P, Schreiner, A

Volltext